← Leaderboards
Mary M. Gerkovich
University Of Missouri Kansas City
$109,866
Attributed
$219,731
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $191.2K · FY2016–17$200K$150K$100K$50K$0
'16
'17
Funding mix
By agency
NIH$219,731 · 1
By mechanism
R21$219,731 · 1
Top collaborators
- William Robert Folk2 shared
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAnimal ModelAmericanAreaArthritic PainArthritisAqueousBiologicalBiological AvailabilityBiological MarkersBotanicalsBurden Of IllnessChronic Low Back PainChronic PainClawClinical EfficacyClinical ProtocolsClinical ResearchClinical Research SiteClinical TrialsCostC-Reactive ProteinCytokineDegenerative Polyarthritis
Grant awards (2)
Phased Exploratory Clinical Studies of Harpagophytum procumbensâ Impact upon the Biological Signature of Inflammatory Osteoarthritis$28,487
R21 · FY2017 · AT · contact PI
Phased Exploratory Clinical Studies of Harpagophytum procumbensâ Impact upon the Biological Signature of Inflammatory Osteoarthritis$191,244
R21 · FY2016 · AT · contact PI